Hormone Therapy

07 Jan

Posted at 22:17h in Author Interviews, Blood Clots, Endocrinology, Hormone Therapy, Pharmacology
[caption id="attachment_20473" align="alignleft" width="160"]Ida Martinelli MD, PhD A Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan, Italy Dr. Martinelli[/caption] MedicalResearch.com Interview with: Ida Martinelli MD, PhD A Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan, Italy  Medical Research: What is the background for this study? What are the main findings? Dr. Martinelli: Hormonal therapies are associated with an increased risk of venous thromboembolism. Patients with acute deep-vein thrombosis or pulmonary embolism require anticoagulation, but women of childbearing potential require also an adequate contraception, as oral anticoagulants cross the placenta potentially leading to embryopathy or fetal bleeding. This study was aimed to evaluate the safety of hormonal therapies together with anticoagulant therapies in terms of recurrent venous thrombosis and uterine bleeding. We demonstrated for the first time that women who take oral anticoagulants can safely use hormonal therapies, as their risk of recurrent venous thromboembolism or uterine bleeding is not increased.

10 Jul

Posted at 20:00h in Author Interviews, Colon Cancer, Hormone Therapy, Menopause, NIH

MedicalResearch.com Interview with: Dr. Hannah Arem Ph.D. M.H.S. Postdoctoral Fellow Nutritional Epidemiology Branch Division Cancer Epidemiology and Genetics National Cancer Institute MedicalResearch: What is the background for this study? Dr. Arem: In the United States, men are more likely to develop colorectal cancer (CRC) than women. In large prospective studies, researchers observed that women who reported...

22 Feb

Posted at 15:12h in Author Interviews, Hormone Therapy, Lancet, Prostate Cancer, Radiation Therapy
Almudena Zapatero MD PhD Senior Consultant Dpt Radiation Oncology Instituto Investigación Sanitaria IIS-IP Hospital Universitario de la Princesa MadridMedicalResearch.com Interview with: Almudena Zapatero MD PhD Senior Consultant Dpt Radiation Oncology Instituto Investigación Sanitaria IIS-IP Hospital Universitario de la Princesa Madrid Medical Research: What is the background for this study? What are the main findings? Dr. Zapatero: There is a significant body of evidence from randomized trials showing a significant improvement in clinical outcome with the combination of androgen deprivation and conventional-dose radiotherapy (≤70 Gy) in patients with high-risk and intermediate-risk prostate cancer. However, the optimal duration the optimum duration of androgen deprivation in the setting of high-dose radiotherapy remained to be determined. The results of our trial (DART01/05) show that 2 years of adjuvant androgen deprivation is superior to 4 months androgen deprivation when combined with plus high-dose radiotherapy  in terms of biochemical control, freedom from metastasis and overall survival, particularly in patients with high-risk prostate cancer.

30 Oct

Posted at 02:48h in Author Interviews, Hormone Therapy, Prostate Cancer
David R. Ziehr B.S., MD Candidate Harvard Medical SchoolMedicalResearch.com Interview with: David R. Ziehr B.S., MD Candidate Harvard Medical School Medical Research: What is the background for this study? What are the main findings? Response: Androgen deprivation therapy (ADT), commonly achieved with gonadotropin-releasing hormone agonists or antagonists, is a mainstay of prostate cancer therapy. While randomized controlled trials demonstrate that ADT improves survival among men with unfavorable risk prostate cancer, retrospective studies have suggested that some men with comorbid illnesses such as heart disease may not derive a benefit from—or may even be harmed by—ADT. However, the nature of this harm has not been characterized. We studied over 5000 men with prostate cancer who were treated with brachytherapy (implanted radioactive seeds) with or without ADT. We analyzed the men based on pre-treatment cardiac comorbidity and examined the association between ADT and death from cardiac causes. We found that among men with congestive heart failure or a past myocardial infarction (MI), Androgen deprivation therapy was associated with a three-times greater risk of death from heart disease. However, Androgen deprivation therapy was not associated with greater risk of cardiac mortality in men without heart disease or with a risk factor for heart disease, such as diabetes, hypertension or hyperlipidemia.

25 Jan

Posted at 13:33h in Author Interviews, BMJ, Hip Fractures, Hormone Therapy, Orthopedics
Professor Nigel Arden Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences Botnar Research Centre Windmill Road Oxford OX3 7LDMedicalResearch.com Interview with: Professor Nigel Arden Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences Botnar Research Centre Oxford  OX3 7LD MedicalResearch.com: What are the main findings of the study? Professor Arden: We found that in a cohort of women who had used hormone replacement therapy (HRT) and underwent knee or hip replacement their risk of implant revision was reduced by about 40% compared to non-users of HRT.

07 Oct

Posted at 00:37h in Author Interviews, Brigham & Women's - Harvard, Hormone Therapy, JAMA, Medical Research Centers, Menopause

MedicalResearch.com Interview with: JoAnn E. Manson, MD, DrPH Chief, Division of Preventive Medicine Brigham and Women's Hospital Professor of Medicine and the Michael and Lee Bell Professor of Women's Health Harvard Medical School Boston , Massachusetts   02215 WHI investigators publish most comprehensive report to date on the two Hormone Therapy Trials and extend follow-up to 13 years:...

28 Jul

Posted at 20:53h in Author Interviews, Hormone Therapy, Neurological Disorders, Parkinson's
Kalipada Pahan, Ph.D. The Floyd A. Davis, M.D., Endowed Chair of Neurology Professor Departments of Neurological Sciences, Biochemistry and Pharmacology Rush University Medical Center 1735 West Harrison St, Suite 320 Chicago, IL 60612MedicalResearch.com Interview with: Kalipada Pahan, Ph.D. The Floyd A. Davis, M.D., Endowed Chair of Neurology Professor Departments of Neurological Sciences, Biochemistry and Pharmacology Rush University Medical Center 1735 West Harrison St, Suite 320 Chicago, IL 60612 MedicalResearch.com: What are the main findings of the study? Dr. Pahan: While different toxins and a number of complex genetic approaches are used to model Parkinson’s disease in mice, this study delineates that simple castration is sufficient to cause persistent Parkinson’s like pathology and symptoms in male mice. This simple, but persistent, model may be helpful in discovering drugs against Parkinson’s disease. Furthermore, these results suggest that sudden drop of testosterone level could trigger Parkinson’s disease.

23 Apr

Posted at 01:21h in Author Interviews, Cancer Research, Chemotherapy, Hormone Therapy
MedicalResearch.com eInterview with Andrew Weickhardt, MBBS, DMedSc, FRACP MedicalResearch.com: What are the main findings of the study? Dr. Weickhardt: The study was hoping to confirm our earlier published observation that crizotinib use led to low testosterone in male patients. The earlier study was based on our observation of symptoms of low testosterone in some patients treated with the drug, and had suggested strongly that crizotinib led to rapid decrease in testosterone levels, however this was based only on a single center's patients, and only 19 patients. We hoped to do this by surveying a larger population of crizotinib treated patients across multiple institutions. We serially measured several relevant hormones.